A Study of SKB264 in Combination with Osimertinib Versus Osimertinib in Patients with Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

420

Participants

Timeline

Start Date

November 27, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

July 31, 2027

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

SKB264

4mg/kg, intravenous (IV) infusion

DRUG

Osimertinib

80mg, QD

Trial Locations (2)

NOT_YET_RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY